Schmidt P J Investment Management Inc. Raises Holdings in Vertex Pharmaceuticals Incorporated $VRTX

Schmidt P J Investment Management Inc. lifted its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 7.8% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 2,082 shares of the pharmaceutical company’s stock after acquiring an additional 150 shares during the period. Schmidt P J Investment Management Inc.’s holdings in Vertex Pharmaceuticals were worth $927,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. GoalVest Advisory LLC grew its stake in shares of Vertex Pharmaceuticals by 3,233.3% during the second quarter. GoalVest Advisory LLC now owns 100 shares of the pharmaceutical company’s stock worth $45,000 after acquiring an additional 97 shares during the last quarter. Banco Santander S.A. grew its stake in shares of Vertex Pharmaceuticals by 9.6% during the second quarter. Banco Santander S.A. now owns 70,188 shares of the pharmaceutical company’s stock worth $31,248,000 after acquiring an additional 6,160 shares during the last quarter. Solstein Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the second quarter worth about $40,000. Signature Wealth Management Group grew its stake in shares of Vertex Pharmaceuticals by 0.6% during the second quarter. Signature Wealth Management Group now owns 4,244 shares of the pharmaceutical company’s stock worth $1,889,000 after acquiring an additional 26 shares during the last quarter. Finally, Resonant Capital Advisors LLC grew its stake in shares of Vertex Pharmaceuticals by 7.4% during the second quarter. Resonant Capital Advisors LLC now owns 1,558 shares of the pharmaceutical company’s stock worth $694,000 after acquiring an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Trading Down 0.3%

Shares of NASDAQ:VRTX opened at $421.39 on Monday. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88. The company has a market capitalization of $108.04 billion, a PE ratio of 30.12 and a beta of 0.43. The business has a 50 day moving average of $398.96 and a two-hundred day moving average of $434.28.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.24 by $0.28. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $2.94 billion during the quarter, compared to the consensus estimate of $2.90 billion. During the same period in the previous year, the company posted ($12.83) earnings per share. Vertex Pharmaceuticals’s revenue for the quarter was up 11.3% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 15.63 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently commented on VRTX. JPMorgan Chase & Co. lifted their target price on Vertex Pharmaceuticals from $517.00 to $530.00 and gave the stock an “overweight” rating in a report on Wednesday, October 8th. Cantor Fitzgerald decreased their target price on Vertex Pharmaceuticals from $535.00 to $485.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Scotiabank decreased their target price on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating for the company in a report on Tuesday, August 5th. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Vertex Pharmaceuticals in a report on Friday. Finally, Evercore ISI decreased their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a report on Thursday, September 11th. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $494.38.

Insider Transactions at Vertex Pharmaceuticals

In related news, Director Bruce I. Sachs purchased 5,000 shares of the firm’s stock in a transaction on Wednesday, August 6th. The stock was bought at an average cost of $389.68 per share, with a total value of $1,948,400.00. Following the completion of the acquisition, the director owned 45,000 shares of the company’s stock, valued at $17,535,600. The trade was a 12.50% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.